5-Amino-1MQ vs Tesofensine

Both are classed here as metabolic compounds, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is fat loss. On this site's goal weighting — an editorial priority score, not a measure of effect size — 5-Amino-1MQ rates 4/5 for fat loss and Tesofensine rates 4/5. Outside that overlap they diverge: 5-Amino-1MQ also carries weight for metabolic health, Tesofensine for appetite control.

This is the part that decides most of it. Tesofensine has approval from a regulator somewhere, though not a current FDA or EMA label — approved in Mexico at 0.5 mg; the 1 mg arm was clearly worse tolerated. 5-Amino-1MQ has animal and cell data only, and no controlled human dosing trials — dose figures are extrapolated from vendor and community practice. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

Tesofensine has a characterized half-life of 9.2 days; 5-Amino-1MQ does not have one published here at all. That asymmetry is worth more than it looks — it usually tracks how much formal pharmacology has been done on a compound.

Committed time differs: 5-Amino-1MQ runs 12 weeks, Tesofensine runs 24 weeks.

5-Amino-1MQ is rated intermediate here and Tesofensine advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.